An open-label, two-period, fixed sequence, randomized, parallel group, interaction study to determine the effects of repeat doses of relacatib on the metabolism of acetaminophen [paracetamol], ibuprofen and atorvastatin in healthy postmenopausal female subjects.
Phase of Trial: Phase I
Latest Information Update: 20 May 2009
At a glance
- Drugs Relacatib (Primary) ; Atorvastatin; Ibuprofen; Paracetamol
- Indications Osteoarthritis; Osteoporosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 20 Apr 2008 Status changed from in progress to completed.
- 03 Jan 2007 New trial record.